Last update 27 Jul 2025

Gemcitabine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
D07001-Softgel, Gemcitabine, Gemcitabine (USAN/INN)
+ [5]
Target
Action
inhibitors
Mechanism
RNR inhibitors(Ribonucleotide reductase inhibitors), DNA synthesis inhibitors
Originator Organization
Inactive Organization
License Organization
Drug Highest PhaseApproved
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC9H11F2N3O4
InChIKeySDUQYLNIPVEERB-QPPQHZFASA-N
CAS Registry95058-81-4

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pancreatic CancerPhase 3-01 Jun 2023
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
Australia
04 Aug 2022
Locally Advanced Pancreatic AdenocarcinomaPhase 3
United States
12 Mar 2018
Locally Advanced Pancreatic AdenocarcinomaPhase 3
Belgium
12 Mar 2018
Advanced Lung Squamous Cell CarcinomaPhase 3
United States
01 Mar 2010
Advanced Lung Squamous Cell CarcinomaPhase 3
Belgium
01 Mar 2010
Advanced Lung Squamous Cell CarcinomaPhase 3
Canada
01 Mar 2010
Advanced Lung Squamous Cell CarcinomaPhase 3
France
01 Mar 2010
Advanced Lung Squamous Cell CarcinomaPhase 3
Germany
01 Mar 2010
Advanced Lung Squamous Cell CarcinomaPhase 3
Hungary
01 Mar 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
89
(Chemotherapy (Cisplatin-Gemcitabine))
wybuuyxgso(lbycsvkkop) = embqwvohid kcbrawmkdx (iaqmfjdszh, caihubtjqs - fvbntsqzqs)
-
09 May 2025
Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)+gemcitabine+Cisplatin
(Radiation: SIRT + Chemotherapy (Cisplatin-Gemcitabine))
wybuuyxgso(lbycsvkkop) = urmyyjxgrr kcbrawmkdx (iaqmfjdszh, bkgtobmacz - uewwocefnc)
Phase 2
82
tgvqoovixy = zpkvqtaziy lmpnjmnvdf (spioyhnpqc, dfdpwbgxha - cqiftgzyvs)
-
24 Apr 2025
Not Applicable
30
aslymzquxr(qaifklyxjb) = kghgcvwdxl ewqqqajwyn (mskoeifnoq )
Positive
13 Feb 2025
Phase 2
23
Radiation Therapy+Gemcitabine+Capecitabine
vvdcwlosmq = hsrqmeatyk rxoucegdkq (kqjvslgdfn, sznibrjtqb - jvxrjdonfv)
-
10 Feb 2025
Phase 2/3
317
Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA)
ncxffduhok(gpzkjatlfy): HR = 1.18 (95% CI, 0.88 - 1.56), P-Value = 0.14
Negative
23 Jan 2025
Phase 3
19
okjsptjuqd(rbefjebnab) = hgwfgesbus nmfpgseols (ysbntexfhg )
Positive
23 Jan 2025
okjsptjuqd(rbefjebnab) = qqgxomsxzg nmfpgseols (ysbntexfhg )
Not Applicable
30
hezarshhxt(ghrvpudxjq) = ssiikobvvo uusablozwm (qztwxubjck )
Positive
23 Jan 2025
Not Applicable
-
Glofitamab with Gemcitabine and Oxaliplatin
pwqlunwlbq(zfisnddcks) = nguorbhufm bcttcpqaan (yhuftznbnx, NA)
-
09 Dec 2024
Rituximab with Gemcitabine and Oxaliplatin
pwqlunwlbq(zfisnddcks) = oegjyurfjk bcttcpqaan (yhuftznbnx, NA)
Not Applicable
-
Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD)
jpsfejwxdh(uxsiuaians) = kfdodvlueo lizywblegx (slefouoxnu )
-
09 Dec 2024
Not Applicable
-
Pembrolizumab Maintenance
qfuwnzeqel(wycajzccot) = kzesuccevn swusciyfcv (adaetjjgkz, 33 - 80)
-
08 Dec 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free